These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37919692)

  • 1. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis.
    Karpecki P; Barghout V; Schenkel B; Huynh L; Khanal A; Mitchell B; Yenikomshian M; Zanardo E; Matossian C
    BMC Ophthalmol; 2023 Nov; 23(1):443. PubMed ID: 37919692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Pharmacologic Therapies for Dry Eye Disease Treatment: Efficacy, Tolerability, and Safety Data Review from Preclinical Studies and Pivotal Trials.
    Shen Lee B; Toyos M; Karpecki P; Schiffbauer J; Sheppard J
    Ophthalmol Ther; 2022 Aug; 11(4):1333-1369. PubMed ID: 35608780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye.
    White DE; Zhao Y; Ogundele A; Fulcher N; Acs A; Moore-Schiltz L; Karpecki PM
    Clin Ophthalmol; 2019; 13():2285-2292. PubMed ID: 31819353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
    Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
    Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease.
    Mandal A; Gote V; Pal D; Ogundele A; Mitra AK
    Pharm Res; 2019 Jan; 36(2):36. PubMed ID: 30617777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
    Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
    Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study.
    Labetoulle M; Leonardi A; Amrane M; Ismail D; Garrigue JS; Garhöfer G; de la Maza MS; Baudouin C
    Clin Ther; 2018 Nov; 40(11):1894-1906. PubMed ID: 30389343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quintessence of currently approved and upcoming treatments for dry eye disease.
    Patil S; Sawale G; Ghuge S; Sathaye S
    Graefes Arch Clin Exp Ophthalmol; 2024 Aug; ():. PubMed ID: 39215848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial.
    Rao AT; Gupta A; Chauhan T; Basu S; Batra N; Sharma N; Sangwan VS; Gupta V; Mukherjee S
    BMC Ophthalmol; 2023 Mar; 23(1):121. PubMed ID: 36973703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease.
    Visco DM; Hendrix LH; Sun L; Tam I; Macsai M; Gibson AA
    J Manag Care Spec Pharm; 2022 Aug; 28(8):892-902. PubMed ID: 35687793
    [No Abstract]   [Full Text] [Related]  

  • 11. Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits.
    Weiss SL; Kramer WG
    J Ocul Pharmacol Ther; 2019 Sep; 35(7):395-402. PubMed ID: 31355703
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study.
    Chen D; Zhang S; Bian A; Hong J; Deng Y; Zhang M; Chen W; Shao Y; Zhao J
    Medicine (Baltimore); 2019 Aug; 98(31):e16710. PubMed ID: 31374063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model.
    Bang SP; Yeon CY; Adhikari N; Neupane S; Kim H; Lee DC; Son MJ; Lee HG; Kim JY; Jun JH
    PLoS One; 2019; 14(11):e0224805. PubMed ID: 31738791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of OTX-101 on Tear Production in Patients with Severe Tear-deficient Dry Eye Disease: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
    Toyos M; Gupta PK; Mitchell B; Karpecki P
    Curr Eye Res; 2022 Feb; 47(2):220-224. PubMed ID: 34459350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
    Sall K; Stevenson OD; Mundorf TK; Reis BL
    Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
    Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
    Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comprehensive Review of the Clinical Trials Conducted for Dry Eye Disease and the Impact of the Vehicle Comparators in These Trials.
    Nichols KK; Evans DG; Karpecki PM
    Curr Eye Res; 2021 May; 46(5):609-614. PubMed ID: 33238774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
    Leonardi A; Messmer EM; Labetoulle M; Amrane M; Garrigue JS; Ismail D; Sainz-de-la-Maza M; Figueiredo FC; Baudouin C
    Br J Ophthalmol; 2019 Jan; 103(1):125-131. PubMed ID: 29545413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra
    Hovanesian JA; Nichols KK; Jackson M; Katz J; Chan A; Glassberg MB; Sloesen B; Korves C; Nguyen C; Syntosi A
    Clin Ophthalmol; 2021; 15():1041-1054. PubMed ID: 33727786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
    Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
    Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.